<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28264500</article-id>
<article-id pub-id-type="pmc">5372543</article-id>
<article-id pub-id-type="doi">10.3390/ijms18030527</article-id>
<article-id pub-id-type="publisher-id">ijms-18-00527</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>GeneAnalytics Pathway Analysis and Genetic Overlap among Autism Spectrum Disorder, Bipolar Disorder and Schizophrenia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Khanzada</surname>
<given-names>Naveen S.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-18-00527">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Butler</surname>
<given-names>Merlin G.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-18-00527">1</xref>
<xref ref-type="aff" rid="af2-ijms-18-00527">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manzardo</surname>
<given-names>Ann M.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-18-00527">1</xref>
<xref ref-type="corresp" rid="c1-ijms-18-00527">*</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Cho</surname>
<given-names>William Chi-shing</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<aff id="af1-ijms-18-00527"><label>1</label>Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS 66160, USA; <email>nkhanzada@kumc.edu</email> (N.S.K.); <email>mbutler4@kumc.edu</email> (M.G.B.)</aff>
<aff id="af2-ijms-18-00527"><label>2</label>Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA</aff>
<author-notes>
<corresp id="c1-ijms-18-00527"><label>*</label>Correspondence: <email>amanzardo@kumc.edu</email>; Tel.: +1-913-588-6473</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2017</year>
</pub-date>
<volume>18</volume>
<issue>3</issue>
<elocation-id>527</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 by the authors.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Bipolar disorder (BPD) and schizophrenia (SCH) show similar neuropsychiatric behavioral disturbances, including impaired social interaction and communication, seen in autism spectrum disorder (ASD) with multiple overlapping genetic and environmental influences implicated in risk and course of illness. GeneAnalytics software was used for pathway analysis and genetic profiling to characterize common susceptibility genes obtained from published lists for ASD (792 genes), BPD (290 genes) and SCH (560 genes). Rank scores were derived from the number and nature of overlapping genes, gene-disease association, tissue specificity and gene functions subdivided into categories (e.g., diseases, tissues or functional pathways). Twenty-three genes were common to all three disorders and mapped to nine biological Superpathways including Circadian entrainment (10 genes, score = 37.0), Amphetamine addiction (five genes, score = 24.2), and Sudden infant death syndrome (six genes, score = 24.1). Brain tissues included the medulla oblongata (11 genes, score = 2.1), thalamus (10 genes, score = 2.0) and hypothalamus (nine genes, score = 2.0) with six common genes (<italic>BDNF</italic>, <italic>DRD2</italic>, <italic>CHRNA7</italic>, <italic>HTR2A</italic>, <italic>SLC6A3</italic>, and <italic>TPH2</italic>). Overlapping genes impacted dopamine and serotonin homeostasis and signal transduction pathways, impacting mood, behavior and physical activity level. Converging effects on pathways governing circadian rhythms support a core etiological relationship between neuropsychiatric illnesses and sleep disruption with hypoxia and central brain stem dysfunction.</p>
</abstract>
<kwd-group>
<kwd>mental illness</kwd>
<kwd>genetic profiling</kwd>
<kwd>GeneAnalytics molecular pathway analysis</kwd>
<kwd>circadian entrainment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-18-00527">
<title>1. Introduction</title>
<p>Severe neuropsychiatric disorders collectively present with similar behavioral, social, cognitive and perceptual disturbances including autism spectrum disorder (ASD). ASD includes classical autism, Asperger syndrome and pervasive developmental disorder with problems in social interaction and communication or repetitive behavior. Schizophrenia (SCH) presents with delusions, hallucinations, disorganized thinking and behavior with negative symptoms. Bipolar disorder (BPD) is considered a developmental disorder characterized by progressive cognitive impairment, residual symptoms, sleep disturbance, and emotional dysregulations with cycles of depression and mania. Schizophrenia and bipolar disorders share many common traits with ASD, including social and cognitive dysfunction and impaired ability to function, live and work independently [<xref ref-type="bibr" rid="B1-ijms-18-00527">1</xref>]. Considerable overlap has been identified between the molecular mechanisms implicated in the etiology of schizophrenia, bipolar disorder, and autism, suggesting similar root causes [<xref ref-type="bibr" rid="B2-ijms-18-00527">2</xref>]. Up to 30% of patients diagnosed with ASD during childhood will develop schizophrenia during adulthood [<xref ref-type="bibr" rid="B3-ijms-18-00527">3</xref>]. Further, the presence of schizophrenia or bipolar disorder in first-degree relatives is a consistent and significant risk factor for ASD [<xref ref-type="bibr" rid="B4-ijms-18-00527">4</xref>]. These three neuropsychiatric illnesses have complex inheritance patterns with &gt;80% estimate for each disorder with multiple genetic and environmental factors influencing disease risk and course [<xref ref-type="bibr" rid="B2-ijms-18-00527">2</xref>,<xref ref-type="bibr" rid="B4-ijms-18-00527">4</xref>].</p>
<p>A recent large collaborative genetic study of families with schizophrenia and ASD showed significant overlap in candidate genes and susceptibility regions for both disorders using traditional karyotyping, genome-wide association studies (GWAS) and comparative genome hybridization (CGH) analyses by identifying chromosomal deletions and duplications in individuals with ASD [<xref ref-type="bibr" rid="B5-ijms-18-00527">5</xref>,<xref ref-type="bibr" rid="B6-ijms-18-00527">6</xref>,<xref ref-type="bibr" rid="B7-ijms-18-00527">7</xref>,<xref ref-type="bibr" rid="B8-ijms-18-00527">8</xref>]. ASD and SCH risk alleles appear to impact growth-signaling pathways with autism associated with loss of function in many genes [<xref ref-type="bibr" rid="B9-ijms-18-00527">9</xref>,<xref ref-type="bibr" rid="B10-ijms-18-00527">10</xref>,<xref ref-type="bibr" rid="B11-ijms-18-00527">11</xref>], whereas schizophrenia tends to be associated with reduced function or activity of genes that up-regulate growth-related pathways [<xref ref-type="bibr" rid="B12-ijms-18-00527">12</xref>,<xref ref-type="bibr" rid="B13-ijms-18-00527">13</xref>,<xref ref-type="bibr" rid="B14-ijms-18-00527">14</xref>,<xref ref-type="bibr" rid="B15-ijms-18-00527">15</xref>,<xref ref-type="bibr" rid="B16-ijms-18-00527">16</xref>].</p>
<p>Cytogenetic, linkage and association studies have identified common copy number variants (CNVs, deletions, duplications) between ASD and SCH which may produce dosage-dependent gain or loss of expression of genes contributing to phenotypic variation in presentation and course of illness. A large number of autism-specific CNVs have been found but with low recurrence (&lt;1%) and they show a high level of genetic heterogeneity. For example, when the 15q11.2 BP1–BP2 region or 15q13.3 band contains a deletion or duplication in patients, then autism or a variety of neuropsychiatric traits including schizophrenia are identified [<xref ref-type="bibr" rid="B3-ijms-18-00527">3</xref>,<xref ref-type="bibr" rid="B17-ijms-18-00527">17</xref>,<xref ref-type="bibr" rid="B18-ijms-18-00527">18</xref>,<xref ref-type="bibr" rid="B19-ijms-18-00527">19</xref>]. Gene expression disturbances were found using postmortem cortical brain tissue from patients with autism, schizophrenia and bipolar disorder and they have shown a high correlation between the transcriptomes of ASD and schizophrenia, but not in BPD [<xref ref-type="bibr" rid="B5-ijms-18-00527">5</xref>]. Hence, a large number of possible genetic and environmental factors do influence disease risk, expression and treatment.</p>
<p>Herein, we use the GeneAnalytics [<xref ref-type="bibr" rid="B20-ijms-18-00527">20</xref>] program pathway analysis to further profile and characterize the underlying molecular architecture of clinically and etiologically relevant genes common to ASD [<xref ref-type="bibr" rid="B21-ijms-18-00527">21</xref>], bipolar disorder [<xref ref-type="bibr" rid="B22-ijms-18-00527">22</xref>] and schizophrenia [<xref ref-type="bibr" rid="B23-ijms-18-00527">23</xref>] and associated diseases.</p>
</sec>
<sec id="sec2-ijms-18-00527">
<title>2. Results</title>
<p>The original gene lists reported in the literature included 792 genes for ASD [<xref ref-type="bibr" rid="B21-ijms-18-00527">21</xref>], 290 genes for bipolar disorder [<xref ref-type="bibr" rid="B22-ijms-18-00527">22</xref>] and 560 genes for schizophrenia [<xref ref-type="bibr" rid="B23-ijms-18-00527">23</xref>], and of these, 23 genes were found in common in all three conditions (see <xref ref-type="table" rid="ijms-18-00527-t001">Table 1</xref>). Functional analysis of the 23 genes identified from the submitted list of genes showed a high match for schizophrenia (17 genes, score = 15.1) with medium-match scores representing 25 other disorders including bipolar disorder (nine genes, score = 9.6) and autism spectrum disorder (10 genes, score = 9.1). Additional diseases identified were related to disorders of mental health including mood and personality disorders (see <xref ref-type="table" rid="ijms-18-00527-t002">Table 2</xref>A). Tissues and cell types profiled for these 23 overlapping genes identified five common types of brain tissues which achieved high match scores (see <xref ref-type="table" rid="ijms-18-00527-t002">Table 2</xref>B). These included the medulla oblongata (11 genes, score = 2.1), thalamus (10 genes, score = 2.0), hypothalamus (nine genes, score = 2.0), hippocampus (nine genes, score = 1.9) and cerebellum (eight genes, score = 1.9). Six (<italic>BDNF</italic>, <italic>DRD2</italic>, C<italic>HRNA7</italic>, <italic>HTR2A</italic>, <italic>SLC6A3</italic>, and <italic>TPH2</italic>) of the overlapping genes were matched to all five tissues types. Sixteen of the overlapping genes matched to a total of 36 Biological Superpathways with a total of nine Superpathways achieving significantly high match scores according to the GeneAnalytics pathway analysis and algorithm [<xref ref-type="bibr" rid="B20-ijms-18-00527">20</xref>]. The Circadian entrainment pathway showed the highest match score involving 10 genes (score = 37.0), followed by Amphetamine addiction involving five genes (score = 24.3) and Sudden infant death syndrome (SIDS) susceptibility pathways (six genes, score = 24.1) (see <xref ref-type="table" rid="ijms-18-00527-t003">Table 3</xref>).</p>
<p>The remaining Superpathways identified did emphasize monoamine signaling and cellular re-uptake/transport. There was little intrinsic overlap between the 36 biological Superpathways with only one gene (<italic>DRD2</italic>) common to all nine Superpathways.</p>
<p>Examination of gene ontology pathways identified 17 genes that matched to a total of 32 GO-molecular functions but high match scores were found for only three molecular functions involving six genes: Serotonin binding with two genes (<italic>HTR2</italic>, <italic>MAOA</italic>) out of nine total pathway genes, score = 14.3; Dopamine binding with two genes (<italic>SLC6A3</italic>, <italic>DRD2</italic>) out of 10 total pathway genes, score = 14) and High Voltage-gated Calcium Channel Activity with two genes (<italic>CACNA1C</italic>, <italic>CACNB2</italic>) out of 10 total pathway genes, score = 14. The 23 overlapping genes mapped to a total of 55 GO-biological processes with high match scores identified for 16 biological processes involving 19 genes (see <xref ref-type="table" rid="ijms-18-00527-t004">Table 4</xref>). These processes involved a variety of behavioral constructs including axon guidance, synaptic transmission, and particularly the activity of ion channels and dopamine homeostasis.</p>
<p>A total of 106 phenotypes were mapped to the 23 overlapping genes with 36 phenotypes involving 18 genes having high match scores (see <xref ref-type="table" rid="ijms-18-00527-t005">Table 5</xref>). The highest-matched phenotypes were behavioral despair (four genes, score = 24.8), hypoactivity (seven genes, score = 24.4), abnormal serotonin levels (four genes, score = 24.1) and abnormal response to novel objects (four genes, score = 22.2). Additionally, phenotypes impacted GABAergic neuron morphology, synaptic transmission and response to hypoxia and risk of death.</p>
</sec>
<sec id="sec3-ijms-18-00527">
<title>3. Discussion</title>
<p>The molecular and genetic architecture of ASD, BPD and SCH with the identified 23 overlapping candidate susceptibility genes common to the three neuropsychiatric illnesses were analyzed to assess shared etiological factors and phenotypes to facilitate mechanistic understanding and potential development of new treatment approaches. Interestingly, the genetic architecture of the overlapping genes for the three disorders converged on brain structures (e.g., medulla oblongata, thalamus), neurotransmitter systems (e.g., dopamine, serotonin) and signal transduction pathways primarily involved in the regulation of circadian oscillations and sleep disturbances. GO-molecular processes were mapped to the neurotransmitter pathways (dopamine, andserotonin) and ion channels (high voltage–gated calcium channels) implicated in mood, addiction and psychotic disorders with regulatory function and expression in brain centers controlling Circadian entrainment.</p>
<p>The human thalamus, hypothalamus and hippocampus have been extensively targeted in relation to relaying and processing sensory and motor information, as well as regulating consciousness and sleep [<xref ref-type="bibr" rid="B24-ijms-18-00527">24</xref>]. The central and peripheral circadian molecular clock is entrained through a complex and highly regulated molecular cascade in the suprachiasmatic nuclei (SCN) of the hypothalamus driven by the cyclical expression of <italic>PER</italic> and <italic>CRY</italic> [<xref ref-type="bibr" rid="B25-ijms-18-00527">25</xref>,<xref ref-type="bibr" rid="B26-ijms-18-00527">26</xref>,<xref ref-type="bibr" rid="B27-ijms-18-00527">27</xref>]. The master lists of susceptibility genes for BPD and SCH contain <italic>CLOCK</italic>, an integral part of the Circadian entrainment pathway, and the identified ASD master gene list contains additional circadian-regulatory genes (e.g., <italic>PER1</italic>, <italic>PER2</italic>, <italic>NPAS2</italic>, <italic>MTNR1A</italic>, and <italic>MTNR1B</italic>). The master clock located in the suprachiasmatic nuclei of the hypothalamus synchronizes mainly by light signals, and releases glutamate and pituitary adenylate cyclase-activating polypeptide (PACAP) with the activation of signal transduction cascades, including nNOS activity, cAMP- and cGMP-dependent protein kinases. Additionally, multiple entrainment pathways converge to phosphorylate CREB and to activate <italic>CLOCK</italic> gene expression [<xref ref-type="bibr" rid="B25-ijms-18-00527">25</xref>,<xref ref-type="bibr" rid="B26-ijms-18-00527">26</xref>,<xref ref-type="bibr" rid="B27-ijms-18-00527">27</xref>] (see <xref ref-type="fig" rid="ijms-18-00527-f001">Figure 1</xref> for circadian pathways and related features).</p>
<p>Arousal and cortical responsiveness are modulated by a complex regulatory network including serotonergic feedback from the median raphe nuclei involved in the regulation of rapid eye movement (REM) sleep patterning [<xref ref-type="bibr" rid="B24-ijms-18-00527">24</xref>]. Depletion of serotonin receptors and feedback are implicated in the pathology of Sudden infant death syndrome (SIDS), a secondary Superpathway identified in our study [<xref ref-type="bibr" rid="B32-ijms-18-00527">32</xref>]. <italic>BDNF</italic>, a neurotrophic factor, and <italic>CHRNA7</italic> genes involved in the SIDS Superpathway were also implicated in the biological processes impacting the response to hypoxia and may reflect underlying vulnerability to neurological/physiological injury secondary to apnea, thereby influencing neurocognition and/or behavior. Mesencephalic dopaminergic neurons from the ventral tegmental area also project to the thalamic nuclei to directly modulate sleep induction and wakefulness through opposing effects of <italic>DRD1</italic> and <italic>DRD2</italic> receptors on adenylyl cyclase activity.</p>
<p>Neuronal activity and plasticity during brain development is sensitive to both neurotransmitter signaling of serotonin and dopamine and responsive to common genetic and environmental factors influencing brain maturation. Monoamine-sensitive periods also modulate select neurodevelopmental processes (e.g., neuron division, migration and dendritic connectivity) involved in the development of behavioral regulation and control as well as sleep patterns, which may reflect core etiological relationships linking neuropsychiatric illnesses to sleep disruption and hypoxia [<xref ref-type="bibr" rid="B28-ijms-18-00527">28</xref>,<xref ref-type="bibr" rid="B33-ijms-18-00527">33</xref>,<xref ref-type="bibr" rid="B34-ijms-18-00527">34</xref>,<xref ref-type="bibr" rid="B35-ijms-18-00527">35</xref>,<xref ref-type="bibr" rid="B36-ijms-18-00527">36</xref>,<xref ref-type="bibr" rid="B37-ijms-18-00527">37</xref>,<xref ref-type="bibr" rid="B38-ijms-18-00527">38</xref>]. Additionally, the homeostatic value of sleep and circadian rhythmicity impact physiology and behavior in important ways, including the response to stress. Rhythmic circadian oscillations in glucocorticoid levels can modulate adult hippocampal growth and functioning through inhibitory effects of glucocorticoid hormones on neural stem cell and progenitor cell proliferation [<xref ref-type="bibr" rid="B39-ijms-18-00527">39</xref>]. Thus, the disruption of circadian entrainment or loss of circadian regulation of glucocorticoid release could directly influence hippocampal neuroplasticity, learning and memory throughout life, which may play a role in psychopathology such as schizophrenia [<xref ref-type="bibr" rid="B40-ijms-18-00527">40</xref>,<xref ref-type="bibr" rid="B41-ijms-18-00527">41</xref>].</p>
<p>Our analyses are limited by the current status of research and availability of published literature reports on candidate genes as well as the reliability of the curated databases and integrated pathway analyses produced by the GeneAnalytics algorithms. Advances in genomic technology and bioinformatics will continue to identify and characterization new candidate genes, but not all identified genes will be equally important or certain to be causative. The relative contributions of any individual gene to the general disease prevalence must be assessed individually. Further, intrinsic bias in the curated literature may result from imbalances in the allocation of resources for study which may overemphasize some disease states or scientific disciplines over others (e.g., genetics of cancer over psychiatry). Nevertheless, the convergence of these model systems and overlaid genetic mechanisms provides relevant insight into the key macro systems involved in pathogenesis and the overlap of these three severe neuropsychiatric disorders.</p>
</sec>
<sec id="sec4-ijms-18-00527">
<title>4. Materials and Methods</title>
<p>We used recently published list of genes found to be clinically relevant and known to play a role in ASD [<xref ref-type="bibr" rid="B21-ijms-18-00527">21</xref>], bipolar disorder [<xref ref-type="bibr" rid="B22-ijms-18-00527">22</xref>] and schizophrenia [<xref ref-type="bibr" rid="B23-ijms-18-00527">23</xref>] for molecular profiling and pathway analysis of genes common to all three neuropsychiatric conditions with similar features. GeneAnalytics (<uri xlink:href="http://geneanalytics.genecards.org/" xlink:type="simple">http://geneanalytics. genecards.org/</uri> [<xref ref-type="bibr" rid="B20-ijms-18-00527">20</xref>]) computer program and genomic databases are part of the GeneCards Suite developed by LifeMap Sciences (<uri xlink:href="http://www.lifemapsc.com/products/genecards-suite-premium-tools/" xlink:type="simple">http://www.lifemapsc.com/products/genecards-suite-premium-tools/</uri>) and were used to map the resultant list of common genes to characterize molecular pathways, biological processes, molecular functions, phenotypes, tissues and cells, diseases and compounds affected by overlapping neuropsychiatric genes.</p>
<p>GeneAnalytics is powered by GeneCards, LifeMap Discovery, MalaCards and PathCards, which combine &gt;100 archived data sources [<xref ref-type="bibr" rid="B20-ijms-18-00527">20</xref>]. The databases contain gene lists for tissues and cells, diseases, phenotypes pathways and compounds curated from published literature reports to develop the best matched list of genes, scored and subdivided into their biological categories such as diseases or pathways. These applications are integrated with GeneCards human gene database, Malacards human disease database, PathCards, human biological pathways database, and LifeMap Discovery tissues and cells database in order to provide an extensive universe of data from human genes, proteins, cells, biological pathways, diseases and their relationships with integration valuable for research and discovery purposes.</p>
<p>Disease matching scores were derived based upon the number of overlapping genes found and the nature of the gene-disease associations. Tissues and cells were scored using a matching algorithm that weighs tissue specificity, abundance and function of the gene. Related pathways were then grouped into Superpathways to improve inferences and pathway enrichment, reduce redundancy and rank genes within a biological mechanism via the multiplicity of constituent pathways with the methodology and algorithm generated by the GeneAnalytics computer-based program. Superpathways were scored based upon transformation of the binomial <italic>p</italic>-value which was equivalent to a corrected <italic>p</italic>-value with significance defined at &lt;0.0001.</p>
</sec>
<sec id="sec5-ijms-18-00527">
<title>5. Conclusions</title>
<p>Genetic overlap among autism spectrum disorder, bipolar disorder and schizophrenia was most strongly mapped to Superpathways and brain tissue types guiding Circadian entrainment. The results illustrate the converging effects of dopamine, serotonin and the signal transduction pathways involved in mood, behavior, cognition and impaired social functions; learning and memory are affected in these neuropsychiatric disorders which also guide brain development and sleep patterning disturbances. Thus, under-recognized sleep dysregulation as a common component of psychiatric illness appears to reflect the underlying molecular and genetic architecture of disease pathology in psychiatric illnesses. The convergence of pathways governing circadian rhythms supports the existence of a common core etiological relationship between neuropsychiatric illness and sleep disruption possibly related to central brain stem dysfunction impacting the presentation and underlying pathology and course of illness. This observation opens a new avenue to pursue for treatment modalities in order to change the clinical outcome and natural history of those affected with these relatively common mental health disorders in our current society.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We acknowledge support from the Consortium for Translational Research on Aggression and Drug Abuse and Dependence (ConTRADA) grant QB864900 from the University of Kansas and the National Institute of Child Health and Human Development (NICHD) grant HD02528. We thank Miwako Karikomi from Kanehisa Laboratories for granting the permission to publish the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways map image.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Naveen Khanzada performed the literature review, compiled information for the GeneAnalytics analysis and primarily composed the manuscript. Merlin Butler contributed to the generation and interpretation of genetic data and the preparation of the manuscript. Ann Manzardo was responsible for the oversight of the study design, implementation, data analysis and interpretation, and manuscript preparation. All of the authors contributed to the final revision and accepted the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ASD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Autism spectrum disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BPD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Bipolar disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SCH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Schizophrenia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GWAS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Genome-wide association studies</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CGH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Comparative genomic hybridization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CNV</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Copy number variants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SIDS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sudden infant death syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SCN</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Suprachiasmatic nuclei</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PACAP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pituitary adenylate cyclase-activating polypeptide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">cAMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">cGAMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cyclic guanosine monophosphate–adenosine monophosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">nNOS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nitric oxide synthase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CREB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">cAMP response element-binding protein</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-18-00527">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders: DSMIV-TR
<edition>4th ed.</edition>
<publisher-name>American Psychiatric Association</publisher-name>
<publisher-loc>Washington, DC, USA</publisher-loc>
<year>2000</year>
</element-citation>
</ref>
<ref id="B2-ijms-18-00527">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carroll</surname><given-names>L.S.</given-names></name><name><surname>Owen</surname><given-names>M.J.</given-names></name></person-group>
<article-title>Genetic overlap between autism, schizophrenia and bipolar disorder</article-title>
<source/>Genome Med.
<year>2009</year>
<volume>1</volume>
<fpage>102</fpage>
<pub-id pub-id-type="doi">10.1186/gm102</pub-id>
<pub-id pub-id-type="pmid">19886976</pub-id></element-citation>
</ref>
<ref id="B3-ijms-18-00527">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burbach</surname><given-names>J.</given-names></name><name><surname>Peter</surname><given-names>H.</given-names></name><name><surname>van der Zwaag</surname><given-names>B.</given-names></name></person-group>
<article-title>Contact in the genetics of autism and schizophrenia</article-title>
<source/>Trends Neurosci.
<year>2009</year>
<volume>32</volume>
<fpage>69</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2008.11.002</pub-id>
<pub-id pub-id-type="pmid">19135727</pub-id></element-citation>
</ref>
<ref id="B4-ijms-18-00527">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>P.F.</given-names></name><name><surname>Magnusson</surname><given-names>C.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Boman</surname><given-names>M.</given-names></name><name><surname>Dalman</surname><given-names>C.</given-names></name><name><surname>Davidson</surname><given-names>M.</given-names></name><name><surname>Fruchter</surname><given-names>E.</given-names></name><name><surname>Hultman</surname><given-names>C.M.</given-names></name><name><surname>Lundberg</surname><given-names>M.</given-names></name><name><surname>Långström</surname><given-names>N.</given-names></name><etal></etal></person-group>
<article-title>Family history of schizophrenia and bipolar disorder as risk factors for autism</article-title>
<source/>Arch. Gen. Psychiatry
<year>2012</year>
<volume>69</volume>
<fpage>1099</fpage>
<lpage>1103</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2012.730</pub-id>
<pub-id pub-id-type="pmid">22752149</pub-id></element-citation>
</ref>
<ref id="B5-ijms-18-00527">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sebat</surname><given-names>J.</given-names></name><name><surname>Lakshmi</surname><given-names>B.</given-names></name><name><surname>Malhotra</surname><given-names>D.</given-names></name><name><surname>Troge</surname><given-names>J.</given-names></name><name><surname>Lese-Martin</surname><given-names>C.</given-names></name><name><surname>Walsh</surname><given-names>T.</given-names></name><name><surname>Yamrom</surname><given-names>B.</given-names></name><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Krasnitz</surname><given-names>A.</given-names></name><name><surname>Kendall</surname><given-names>J.</given-names></name><etal></etal></person-group>
<article-title>Strong association of de novo copy number mutations with autism</article-title>
<source/>Science
<year>2007</year>
<volume>316</volume>
<fpage>445</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1126/science.1138659</pub-id>
<pub-id pub-id-type="pmid">17363630</pub-id></element-citation>
</ref>
<ref id="B6-ijms-18-00527">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Szatmari</surname><given-names>P.</given-names></name><name><surname>Paterson</surname><given-names>A.D.</given-names></name><name><surname>Zwaigenbaum</surname><given-names>L.</given-names></name><name><surname>Roberts</surname><given-names>W.</given-names></name><name><surname>Brian</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.Q.</given-names></name><name><surname>Vincent</surname><given-names>J.B.</given-names></name><name><surname>Skaug</surname><given-names>J.L.</given-names></name><name><surname>Thompson</surname><given-names>A.P.</given-names></name><name><surname>Senman</surname><given-names>L.</given-names></name><etal></etal></person-group>
<article-title>Autism Genome Project Consortium, Mapping autism risk loci using genetic linkage and chromosomal rearrangments</article-title>
<source/>Nat. Genet.
<year>2007</year>
<volume>39</volume>
<fpage>319</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1038/ng1985</pub-id>
<pub-id pub-id-type="pmid">17322880</pub-id></element-citation>
</ref>
<ref id="B7-ijms-18-00527">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marshall</surname><given-names>C.R.</given-names></name><name><surname>Noor</surname><given-names>A.</given-names></name><name><surname>Vincent</surname><given-names>J.B.</given-names></name><name><surname>Lionel</surname><given-names>A.C.</given-names></name><name><surname>Feuk</surname><given-names>L.</given-names></name><name><surname>Skaug</surname><given-names>J.</given-names></name><name><surname>Shago</surname><given-names>M.</given-names></name><name><surname>Moessner</surname><given-names>R.</given-names></name><name><surname>Pinto</surname><given-names>D.</given-names></name><name><surname>Ren</surname><given-names>Y.</given-names></name><etal></etal></person-group>
<article-title>Structural variation of chromosomes in autism spectrum disorder</article-title>
<source/>Am. J. Hum. Genet.
<year>2008</year>
<volume>82</volume>
<fpage>477</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2007.12.009</pub-id>
<pub-id pub-id-type="pmid">18252227</pub-id></element-citation>
</ref>
<ref id="B8-ijms-18-00527">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.G.</given-names></name><name><surname>Kishikawa</surname><given-names>S.</given-names></name><name><surname>Higgins</surname><given-names>A.W.</given-names></name><name><surname>Seong</surname><given-names>I.S.</given-names></name><name><surname>Donovan</surname><given-names>D.J.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Lally</surname><given-names>E.</given-names></name><name><surname>Weiss</surname><given-names>L.A.</given-names></name><name><surname>Najm</surname><given-names>J.</given-names></name><name><surname>Kutsche</surname><given-names>K.</given-names></name><etal></etal></person-group>
<article-title>Disruption of neurexin 1 associated with autism spectrum disorder</article-title>
<source/>Am. J. Hum. Genet.
<year>2008</year>
<volume>82</volume>
<fpage>199</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2007.09.011</pub-id>
<pub-id pub-id-type="pmid">18179900</pub-id></element-citation>
</ref>
<ref id="B9-ijms-18-00527">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belmonte</surname><given-names>M.K.</given-names></name><name><surname>Bourgeron</surname><given-names>T.</given-names></name></person-group>
<article-title>Fragile X syndrome and autism at the intersection of genetic and neural networks</article-title>
<source/>Nat. Neurosci.
<year>2006</year>
<volume>9</volume>
<fpage>1221</fpage>
<lpage>1225</lpage>
<pub-id pub-id-type="doi">10.1038/nn1765</pub-id>
<pub-id pub-id-type="pmid">17001341</pub-id></element-citation>
</ref>
<ref id="B10-ijms-18-00527">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>C.H.</given-names></name><name><surname>Luikart</surname><given-names>B.W.</given-names></name><name><surname>Powell</surname><given-names>C.M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Matheny</surname><given-names>S.A.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Baker</surname><given-names>S.J.</given-names></name><name><surname>Parada</surname><given-names>L.F.</given-names></name></person-group>
<article-title>Pten regulates neuronal arborization and social interaction in mice</article-title>
<source/>Neuron
<year>2006</year>
<volume>50</volume>
<fpage>377</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2006.03.023</pub-id>
<pub-id pub-id-type="pmid">16675393</pub-id></element-citation>
</ref>
<ref id="B11-ijms-18-00527">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoeffer</surname><given-names>C.A.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Wong</surname><given-names>H.</given-names></name><name><surname>Santillan</surname><given-names>A.</given-names></name><name><surname>Patterson</surname><given-names>R.J.</given-names></name><name><surname>Martinez</surname><given-names>L.A.</given-names></name><name><surname>Tejada-Simon</surname><given-names>M.V.</given-names></name><name><surname>Paylor</surname><given-names>R.</given-names></name><name><surname>Hamilton</surname><given-names>S.L.</given-names></name><name><surname>Klann</surname><given-names>E.</given-names></name></person-group>
<article-title>Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior</article-title>
<source/>Neuron
<year>2008</year>
<volume>60</volume>
<fpage>832</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2008.09.037</pub-id>
<pub-id pub-id-type="pmid">19081378</pub-id></element-citation>
</ref>
<ref id="B12-ijms-18-00527">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cuscó</surname><given-names>I.</given-names></name><name><surname>Medrano</surname><given-names>A.</given-names></name><name><surname>Gener</surname><given-names>B.</given-names></name><name><surname>Vilardell</surname><given-names>M.</given-names></name><name><surname>Gallastegui</surname><given-names>F.</given-names></name><name><surname>Villa</surname><given-names>O.</given-names></name><name><surname>González</surname><given-names>E.</given-names></name><name><surname>Rodríguez-Santiago</surname><given-names>B.</given-names></name><name><surname>Vilella</surname><given-names>E.</given-names></name><name><surname>del Campo</surname><given-names>M.</given-names></name><etal></etal></person-group>
<article-title>Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder</article-title>
<source/>Hum. Mol. Genet.
<year>2009</year>
<volume>18</volume>
<fpage>1795</fpage>
<lpage>1804</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp092</pub-id>
<pub-id pub-id-type="pmid">19246517</pub-id></element-citation>
</ref>
<ref id="B13-ijms-18-00527">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emamian</surname><given-names>E.S.</given-names></name><name><surname>Hall</surname><given-names>D.</given-names></name><name><surname>Birnbaum</surname><given-names>M.J.</given-names></name><name><surname>Karayiorgou</surname><given-names>M.</given-names></name><name><surname>Gogos</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia</article-title>
<source/>Nat. Genet.
<year>2004</year>
<volume>36</volume>
<fpage>131</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1038/ng1296</pub-id>
<pub-id pub-id-type="pmid">14745448</pub-id></element-citation>
</ref>
<ref id="B14-ijms-18-00527">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stopkova</surname><given-names>P.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Papolos</surname><given-names>D.F.</given-names></name><name><surname>Vevera</surname><given-names>J.</given-names></name><name><surname>Paclt</surname><given-names>I.</given-names></name><name><surname>Zukov</surname><given-names>I.</given-names></name><name><surname>Bersson</surname><given-names>Y.B.</given-names></name><name><surname>Margolis</surname><given-names>B.A.</given-names></name><name><surname>Strous</surname><given-names>R.D.</given-names></name><name><surname>Lachman</surname><given-names>H.M.</given-names></name></person-group>
<article-title>Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia</article-title>
<source/>Biol. Psychiatry
<year>2004</year>
<volume>55</volume>
<fpage>981</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.01.014</pub-id>
<pub-id pub-id-type="pmid">15121481</pub-id></element-citation>
</ref>
<ref id="B15-ijms-18-00527">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalkman</surname><given-names>H.O.</given-names></name></person-group>
<article-title>The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia</article-title>
<source/>Pharmacol. Ther.
<year>2006</year>
<volume>110</volume>
<fpage>117</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2005.10.014</pub-id>
<pub-id pub-id-type="pmid">16434104</pub-id></element-citation>
</ref>
<ref id="B16-ijms-18-00527">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krivosheya</surname><given-names>D.</given-names></name><name><surname>Tapia</surname><given-names>L.</given-names></name><name><surname>Levinson</surname><given-names>J.N.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Hines</surname><given-names>R.</given-names></name><name><surname>Ting</surname><given-names>A.K.</given-names></name><name><surname>Craig</surname><given-names>A.M.</given-names></name><name><surname>Mei</surname><given-names>L.</given-names></name><name><surname>Bamji</surname><given-names>S.X.</given-names></name><etal></etal></person-group>
<article-title>ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms</article-title>
<source/>J. Biol. Chem.
<year>2008</year>
<volume>283</volume>
<fpage>32944</fpage>
<lpage>32956</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M800073200</pub-id>
<pub-id pub-id-type="pmid">18819924</pub-id></element-citation>
</ref>
<ref id="B17-ijms-18-00527">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cox</surname><given-names>D.M.</given-names></name><name><surname>Butler</surname><given-names>M.G.</given-names></name></person-group>
<article-title>The 15q11.2 BP1–BP2 microdeletion syndrome: A review</article-title>
<source/>Int. J. Mol. Sci.
<year>2015</year>
<volume>16</volume>
<fpage>4068</fpage>
<lpage>4082</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16024068</pub-id>
<pub-id pub-id-type="pmid">25689425</pub-id></element-citation>
</ref>
<ref id="B18-ijms-18-00527">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burnside</surname><given-names>R.D.</given-names></name><name><surname>Pasion</surname><given-names>R.</given-names></name><name><surname>Mikhail</surname><given-names>F.M.</given-names></name><name><surname>Carroll</surname><given-names>A.J.</given-names></name><name><surname>Robin</surname><given-names>N.H.</given-names></name><name><surname>Youngs</surname><given-names>E.L.</given-names></name><name><surname>Gadi</surname><given-names>I.K.</given-names></name><name><surname>Keitges</surname><given-names>E.</given-names></name><name><surname>Jaswaney</surname><given-names>V.L.</given-names></name><name><surname>Papenhausen</surname><given-names>P.R.</given-names></name><etal></etal></person-group>
<article-title>Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: A susceptibility region for neurological dysfunction including developmental and language delay</article-title>
<source/>Hum. Genet.
<year>2011</year>
<volume>130</volume>
<fpage>517</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-011-0970-4</pub-id>
<pub-id pub-id-type="pmid">21359847</pub-id></element-citation>
</ref>
<ref id="B19-ijms-18-00527">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>K.S.</given-names></name><name><surname>Wassman</surname><given-names>E.R.</given-names></name><name><surname>Baxter</surname><given-names>A.L.</given-names></name><name><surname>Hensel</surname><given-names>C.H.</given-names></name><name><surname>Martin</surname><given-names>M.M.</given-names></name><name><surname>Prasad</surname><given-names>A.</given-names></name><name><surname>Twede</surname><given-names>H.</given-names></name><name><surname>Vanzo</surname><given-names>R.J.</given-names></name><name><surname>Butler</surname><given-names>M.G.</given-names></name></person-group>
<article-title>Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders using an ultra-high resolution chromosomal microarray optimized for neurodevelopmental disorders</article-title>
<source/>Int. J. Mol. Sci.
<year>2016</year>
<volume>17</volume>
<elocation-id>2070</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms17122070</pub-id>
<pub-id pub-id-type="pmid">27941670</pub-id></element-citation>
</ref>
<ref id="B20-ijms-18-00527">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>F.S.</given-names></name><name><surname>Lieder</surname><given-names>I.</given-names></name><name><surname>Stelzer</surname><given-names>G.</given-names></name><name><surname>Mazor</surname><given-names>Y.</given-names></name><name><surname>Buzhor</surname><given-names>E.</given-names></name><name><surname>Kaplan</surname><given-names>S.</given-names></name><name><surname>Bogoch</surname><given-names>Y.</given-names></name><name><surname>Plaschkes</surname><given-names>I.</given-names></name><name><surname>Shitrit</surname><given-names>A.</given-names></name><name><surname>Rappaport</surname><given-names>N.</given-names></name><etal></etal></person-group>
<article-title>GeneAnalytics: An integrative gene set analysis tool for next generation sequencing, RNAseq and microarray data</article-title>
<source/>OMICS J. Integr. Biol.
<year>2016</year>
<volume>20</volume>
<fpage>139</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1089/omi.2015.0168</pub-id>
<pub-id pub-id-type="pmid">26983021</pub-id></element-citation>
</ref>
<ref id="B21-ijms-18-00527">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>M.G.</given-names></name><name><surname>Rafi</surname><given-names>S.K.</given-names></name><name><surname>Manzardo</surname><given-names>A.M.</given-names></name></person-group>
<article-title>High-resolution chromosome ideogram representation of currently recognized genes for autism spectrum disorders</article-title>
<source/>Int. J. Mol. Sci.
<year>2015</year>
<volume>16</volume>
<fpage>6464</fpage>
<lpage>6495</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16036464</pub-id>
<pub-id pub-id-type="pmid">25803107</pub-id></element-citation>
</ref>
<ref id="B22-ijms-18-00527">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Douglas</surname><given-names>L.N.</given-names></name><name><surname>McGuire</surname><given-names>A.B.</given-names></name><name><surname>Manzardo</surname><given-names>A.M.</given-names></name><name><surname>Butler</surname><given-names>M.G.</given-names></name></person-group>
<article-title>High-resolution chromosome ideogram representation of recognized genes for bipolar disorder</article-title>
<source/>Gene
<year>2016</year>
<volume>586</volume>
<fpage>136</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2016.04.011</pub-id>
<pub-id pub-id-type="pmid">27063557</pub-id></element-citation>
</ref>
<ref id="B23-ijms-18-00527">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>M.G.</given-names></name><name><surname>McGuire</surname><given-names>A.B.</given-names></name><name><surname>Masoud</surname><given-names>H.</given-names></name><name><surname>Manzardo</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Currently recognized genes for schizophrenia: High-resolution chromosome ideogram representation</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet. Part B
<year>2016</year>
<volume>1B</volume>
<fpage>181</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32391</pub-id>
<pub-id pub-id-type="pmid">26462458</pub-id></element-citation>
</ref>
<ref id="B24-ijms-18-00527">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weber</surname><given-names>F.</given-names></name><name><surname>Chung</surname><given-names>S.</given-names></name><name><surname>Beier</surname><given-names>K.T.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Dan</surname><given-names>Y.</given-names></name></person-group>
<article-title>Control of REM sleep by ventral medulla GABAergic neurons</article-title>
<source/>Nature
<year>2015</year>
<volume>526</volume>
<fpage>435</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1038/nature14979</pub-id>
<pub-id pub-id-type="pmid">26444238</pub-id></element-citation>
</ref>
<ref id="B25-ijms-18-00527">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reischl</surname><given-names>S.</given-names></name><name><surname>Kramer</surname><given-names>A.</given-names></name></person-group>
<article-title>Kinases and phosphatases in the mammalian circadian clock</article-title>
<source/>FEBS Lett.
<year>2011</year>
<volume>585</volume>
<fpage>1393</fpage>
<lpage>1399</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2011.02.038</pub-id>
<pub-id pub-id-type="pmid">21376720</pub-id></element-citation>
</ref>
<ref id="B26-ijms-18-00527">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Klein</surname><given-names>P.S.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Nuclear receptor Rev-Erbα is a critical lithium-sensitive component of the circadian clock</article-title>
<source/>Science
<year>2006</year>
<volume>311</volume>
<fpage>1002</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="doi">10.1126/science.1121613</pub-id>
<pub-id pub-id-type="pmid">16484495</pub-id></element-citation>
</ref>
<ref id="B27-ijms-18-00527">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeidner</surname><given-names>L.C.</given-names></name><name><surname>Buescher</surname><given-names>J.L.</given-names></name><name><surname>Phiel</surname><given-names>C.J.</given-names></name></person-group>
<article-title>A novel interaction between Glycogen Synthase Kinase-3α (GSK-3α) and the scaffold protein receptor for activated C-Kinase 1 (RACK1) regulates the circadian clock</article-title>
<source/>Int. J. Biochem. Mol. Biol.
<year>2011</year>
<volume>2</volume>
<fpage>318</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">22187666</pub-id></element-citation>
</ref>
<ref id="B28-ijms-18-00527">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarazi</surname><given-names>F.I.</given-names></name><name><surname>Tomasini</surname><given-names>E.C.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Postnatal development of dopamine D4-like receptors in rat forebrain regions: Comparison with D2-like receptors</article-title>
<source/>Brain Res. Dev. Brain Res.
<year>1998</year>
<volume>110</volume>
<fpage>227</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-3806(98)00111-4</pub-id>
<pub-id pub-id-type="pmid">9748595</pub-id></element-citation>
</ref>
<ref id="B29-ijms-18-00527">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Morishima</surname><given-names>K.</given-names></name></person-group>
<article-title>KEGG: New perspectives on genomes, pathways, diseases and drugs</article-title>
<source/>Nucleic Acids Res.
<year>2017</year>
<volume>45</volume>
<fpage>D353</fpage>
<lpage>D361</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
<pub-id pub-id-type="pmid">27899662</pub-id></element-citation>
</ref>
<ref id="B30-ijms-18-00527">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Kawashima</surname><given-names>M.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name></person-group>
<article-title>KEGG as a reference resource for gene and protein annotation</article-title>
<source/>Nucleic Acids Res.
<year>2016</year>
<volume>44</volume>
<fpage>D457</fpage>
<lpage>D462</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id>
<pub-id pub-id-type="pmid">26476454</pub-id></element-citation>
</ref>
<ref id="B31-ijms-18-00527">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>S.</given-names></name></person-group>
<article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title>
<source/>Nucleic Acids Res.
<year>2000</year>
<volume>28</volume>
<fpage>27</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id>
<pub-id pub-id-type="pmid">10592173</pub-id></element-citation>
</ref>
<ref id="B32-ijms-18-00527">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavezzi</surname><given-names>A.M.</given-names></name><name><surname>Casale</surname><given-names>V.</given-names></name><name><surname>Oneda</surname><given-names>R.</given-names></name><name><surname>Weese-Mayer</surname><given-names>D.E.</given-names></name><name><surname>Matturri</surname><given-names>L.</given-names></name></person-group>
<article-title>Sudden infant death syndrome and sudden intrauterine unexplained death: Correlation between hypoplasia of raphé nuclei and serotonin transporter gene promoter polymorphism</article-title>
<source/>Pediatr. Res.
<year>2009</year>
<volume>66</volume>
<fpage>22</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1203/PDR.0b013e3181a7bb73</pub-id>
<pub-id pub-id-type="pmid">19342987</pub-id></element-citation>
</ref>
<ref id="B33-ijms-18-00527">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Severson</surname><given-names>C.A.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Pieribone</surname><given-names>V.A.</given-names></name><name><surname>Dohle</surname><given-names>C.I.</given-names></name><name><surname>Richerson</surname><given-names>G.B.</given-names></name></person-group>
<article-title>Midbrain serotoninergic neurons are central pH chemoreceptors</article-title>
<source/>Nat. Neurosci.
<year>2003</year>
<volume>6</volume>
<fpage>1139</fpage>
<lpage>1140</lpage>
<pub-id pub-id-type="doi">10.1038/nn1130</pub-id>
<pub-id pub-id-type="pmid">14517544</pub-id></element-citation>
</ref>
<ref id="B34-ijms-18-00527">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>P.</given-names></name><name><surname>Cases</surname><given-names>O.</given-names></name><name><surname>Maroteaux</surname><given-names>L.</given-names></name></person-group>
<article-title>The developmental role of serotonin: News from mouse molecular genetics</article-title>
<source/>Nat. Rev. Neurosci.
<year>2003</year>
<volume>4</volume>
<fpage>1002</fpage>
<lpage>1012</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1256</pub-id>
<pub-id pub-id-type="pmid">14618156</pub-id></element-citation>
</ref>
<ref id="B35-ijms-18-00527">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haydon</surname><given-names>P.G.</given-names></name><name><surname>McCobb</surname><given-names>D.P.</given-names></name><name><surname>Kater</surname><given-names>S.B.</given-names></name></person-group>
<article-title>Serotonin selectively inhibits growth cone motility and synaptogenesis of specific identified neurons</article-title>
<source/>Science
<year>1984</year>
<volume>226</volume>
<fpage>561</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1126/science.6093252</pub-id>
<pub-id pub-id-type="pmid">6093252</pub-id></element-citation>
</ref>
<ref id="B36-ijms-18-00527">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lauder</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Ontogeny of the serotonergic system in the rat: Serotonin as a developmental signal</article-title>
<source/>Ann. N. Y. Acad. Sci.
<year>1990</year>
<volume>600</volume>
<fpage>297</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1990.tb16891.x</pub-id>
<pub-id pub-id-type="pmid">2252317</pub-id></element-citation>
</ref>
<ref id="B37-ijms-18-00527">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>D.</given-names></name><name><surname>Lueras</surname><given-names>P.</given-names></name><name><surname>Bhide</surname><given-names>P.G.</given-names></name></person-group>
<article-title>Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers</article-title>
<source/>Brain Res.
<year>2007</year>
<volume>1182</volume>
<fpage>11</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2007.08.088</pub-id>
<pub-id pub-id-type="pmid">17950709</pub-id></element-citation>
</ref>
<ref id="B38-ijms-18-00527">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Popolo</surname><given-names>M.</given-names></name><name><surname>McCarthy</surname><given-names>D.M.</given-names></name><name><surname>Bhide</surname><given-names>P.</given-names></name></person-group>
<article-title>Influence of dopamine on precursor cell proliferation and differentiation in the embryonic mouse telencephalon</article-title>
<source/>Dev. Neurosci.
<year>2004</year>
<volume>26</volume>
<fpage>229</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1159/000082140</pub-id>
<pub-id pub-id-type="pmid">15711063</pub-id></element-citation>
</ref>
<ref id="B39-ijms-18-00527">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fitzsimons</surname><given-names>C.P.</given-names></name><name><surname>Herbert</surname><given-names>J.</given-names></name><name><surname>Schouten</surname><given-names>M.</given-names></name><name><surname>Meijer</surname><given-names>O.C.</given-names></name><name><surname>Lucassen</surname><given-names>P.J.</given-names></name><name><surname>Lightman</surname><given-names>S.</given-names></name></person-group>
<article-title>Circadian and ultradian glucocorticoid rhythmicity: Implications for the effects of glucocorticoids on neural stem cells and adult hippocampal neurogenesis</article-title>
<source/>Front. Neuroendocrinol.
<year>2016</year>
<volume>41</volume>
<fpage>44</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.yfrne.2016.05.001</pub-id>
<pub-id pub-id-type="pmid">27234350</pub-id></element-citation>
</ref>
<ref id="B40-ijms-18-00527">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tam</surname><given-names>S.K.</given-names></name><name><surname>Pritchett</surname><given-names>D.</given-names></name><name><surname>Brown</surname><given-names>L.A.</given-names></name><name><surname>Foster</surname><given-names>R.G.</given-names></name><name><surname>Bannerman</surname><given-names>D.M.</given-names></name><name><surname>Peirson</surname><given-names>S.N.</given-names></name></person-group>
<article-title>Sleep and circadian rhythm disruption and recognition memory in schizophrenia</article-title>
<source/>Methods Enzymol.
<year>2015</year>
<volume>552</volume>
<fpage>325</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="pmid">25707284</pub-id></element-citation>
</ref>
<ref id="B41-ijms-18-00527">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyer</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>T.A.</given-names></name><name><surname>Gillette</surname><given-names>M.U.</given-names></name></person-group>
<article-title>Circadian gating of neuronal functionality: A basis for iterative metaplasticity</article-title>
<source/>Front. Syst. Neurosci.
<year>2014</year>
<volume>8</volume>
<fpage>164</fpage>
<pub-id pub-id-type="doi">10.3389/fnsys.2014.00164</pub-id>
<pub-id pub-id-type="pmid">25285070</pub-id></element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-18-00527-f001" position="float">
<label>Figure 1</label>
<caption>
<p>Circadian entrainment is an intrinsic, internal biological clock entrained by exogenous signals, such as endocrine and behavioral rhythms synchronized to environmental cues. The master clock located in the suprachiasmatic nuclei (SCN) of the hypothalamus synchronizes circadian oscillators in peripheral tissues. The main photic input to the suprachiasmatic nuclei comes from the retinal ganglion cells which use glutamate and PACAP, which leads to activation of AMPA and NMDA receptors. The release of glutamate and PACAP triggers the activation of signal transduction cascades including CamKII and nNOS activity, cAMP- and cGMP-dependent protein kinases and mitogen-activated protein kinase (MAPK). Also, melatonin affects non-photic entrainment by inhibiting light-induced phase shifts through inhibition of adenylate cyclase (AC). Additionally, multiple entrainment pathways converge to phosphorylate CREB and to activate <italic>CLOCK</italic> gene expression [<xref ref-type="bibr" rid="B28-ijms-18-00527">28</xref>,<xref ref-type="bibr" rid="B29-ijms-18-00527">29</xref>,<xref ref-type="bibr" rid="B30-ijms-18-00527">30</xref>,<xref ref-type="bibr" rid="B31-ijms-18-00527">31</xref>]. Solid and dotted lines indicate direct and indirect relationships, respectively.</p>
</caption>
<graphic xlink:href="ijms-18-00527-g001"></graphic>
</fig>
<table-wrap id="ijms-18-00527-t001" position="float">
<object-id pub-id-type="pii">ijms-18-00527-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Twenty-three clinically relevant genes common to ASD, BPD and schizophrenia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Symbol</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Chromosome Location</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>BDNF</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Brain-derived neurotrophic factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11p14.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ANK3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ankyrin 3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10q21.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CACNA1C</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ca<sup>2</sup>+ channel, voltage-dependent, L type, α1C subunit</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12p13.33</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CACNB2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ca+ channel, voltage dependent, β2 subunit</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10p12.33</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CHRNA7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cholinergic receptor, nicotinic, α7 (neuronal)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">15q13.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CNTNAP5</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Contactin associated protein-like 5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2q14.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CSMD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CUB and sushi multiple domains 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8p23.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>DISC1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Disruption in schizophrenia 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q42.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>DPP10</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Dipeptidyl-peptidase 10 (non-functional)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2q14.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>DRD2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Dopamine receptor D2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11q23.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>FOXP2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Forkhead box P2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7q31.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>GSK3B</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Glycogen synthase kinase 3β</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3q13.33</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HTR2A</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5-Hydroxytryptamine (serotonin) receptor 2A, G-protein-coupled</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13q14.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MAOA</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Monoamine oxidase A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Xp11.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MTHFR</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Methylenetetrahydrofolate reductase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1p36.22</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NOS1AP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nitric oxide synthase 1 (neuronal) adaptor protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q23.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NRG1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuregulin 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8p12</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PDE4B</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Phosphodiesterase 4B, CAMP-specific</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1p31.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>SLC6A3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5p15.33</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>SYN3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Synapsin III</td>
<td align="center" colspan="1" rowspan="1" valign="middle">22q12.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>TCF4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription factor 4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">18q21.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>TPH2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tryptophan hydroxylase 2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12q21.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ZNF804A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Zinc finger protein 804 A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q32.1</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-18-00527-t002" position="float">
<object-id pub-id-type="pii">ijms-18-00527-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>GeneAnalytics program mapping of diseases, tissues and cells that were significantly matched to 23 overlapping genes for autism spectrum disorder, bipolar disorder and schizophrenia.</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>A. Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>Genes Matched to Disease Type (Highmatch Score)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>No. of Genes in Disease Type</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>Score</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>ANK3</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>CHRNA7</italic>, <italic>DISC1</italic>, <italic>NRG1</italic>, <italic>DRD2</italic>, <italic>GSK3B</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>MTHFR</italic>, <italic>NOS1AP</italic>, <italic>PDE4B</italic>, <italic>SLC6A3</italic>, <italic>SYN3</italic>, <italic>TPH2</italic>, <italic>ZNF804A</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">249</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">(Mediummatch scores &gt; 6.0)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bipolar disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>GSK3B</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NRG1</italic>, <italic>SLC6A3</italic>, <italic>ZNF804A</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">39</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Autism spectrum disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>FOXP2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>MTHFR</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">103</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Disease of mental health</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NRG1</italic>, <italic>SLC6A3</italic>, <italic>ZNF804A</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">57</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Attention deficit hyperactivity disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic>, <italic>ZNF804A</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">63</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mood disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">31</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Psychotic disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>NRG1</italic>, <italic>SLC6A3</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">37</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Anxiety disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Obsessive compulsive disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">29</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6.8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Personality disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>B. Tissues and Cells</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Genes Matched to Tissues and Cells</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>No. of Genes in Tissues And Cells</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Score</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Medulla oblongata</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic>, <italic>FOXP2</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NRG1</italic>, <italic>PDE4B</italic>, <italic>SLC6A3</italic>, <italic>TCF4</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2179</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thalamus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic>, <italic>MTHFR</italic>, <italic>PDE4B</italic>, <italic>SLC6A3</italic>, <italic>TCF4</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1736</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hypothalamus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic>, <italic>FOXP2</italic>, <italic>HTR2A</italic>, <italic>MTHFR</italic>, <italic>PDE4B</italic>, <italic>SLC6A3</italic>, <italic>TCF4</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1666</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hippocampus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>ANK3</italic>, <italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DISC1</italic>, <italic>DRD2</italic>, <italic>FOXP2</italic>, <italic>HTR2A</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3335</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.9</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cerebellum</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>ANK3</italic>, <italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic>, <italic>FOXP2</italic>, <italic>HTR2A</italic>, <italic>SLC6A3</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2609</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.9</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-18-00527-t003" position="float">
<object-id pub-id-type="pii">ijms-18-00527-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>GeneAnalytics program mapping of superpathways with high match scores for 23 overlapping genes for autism spectrum disorder, bipolar disorder and schizophrenia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Superpathways</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Genes Matched to Superpathways</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">No. of Genes in Superpathways</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Score</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Circadian entrainment</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>GSK3B</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NOS1AP</italic>, <italic>PDE4B</italic>, <italic>TPH2</italic>, <italic>CACNA1C</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">390</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">37.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Amphetamine addiction</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">87</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SID susceptibility pathways</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NOS1AP</italic>, <italic>TPH2</italic>, <italic>BDNF</italic>, <italic>CHRNA7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">185</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Selective serotonin reuptake inhibitor pathways</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">29</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Monoamine transport</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic>, <italic>TPH2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">36</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transmission across chemical synapses</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic>, <italic>SYN3</italic>, <italic>CACNB2</italic>, <italic>CHRNA7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">316</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CREB pathways</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>NRG1</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>CACNB2</italic>, <italic>CHRNA7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">562</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.9</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neurotransmitter clearance in the synaptic cleft</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CAMP signaling pathways</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>PDE4B</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">211</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.4</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-18-00527-t004" position="float">
<object-id pub-id-type="pii">ijms-18-00527-t004_Table 4</object-id>
<label>Table 4</label>
<caption>
<p>GeneAnalytics program mapping of gene ontology (GO) biological processes with high match scores to 23 overlapping genes for autism spectrum disorder, bipolar disorder and schizophrenia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">GO-Biological Processes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Genes Matched to GO-Biological Processes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">No. of Genes in GO-Biological Processes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Score</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Startle response</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>CSMD1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Positive regulation of axon extension</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>GSK3B</italic>, <italic>NRG1</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cellular calcium ion homeostasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>CACNA1C</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">107</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Synaptic transmission</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>CACNA1C</italic>, <italic>CACNB2</italic>, <italic>CHRNA7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">432</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dopamine catabolic process</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Axon guidance</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>GSK3B</italic>, <italic>NRG1</italic>, <italic>ANK3</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>CACNB2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">537</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Synapse assembly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>BDNF</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">52</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of high voltage-gated calcium channel activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NOS1AP</italic>, <italic>PDE4B</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of potassium Ion transport</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>ANK3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Response to hypoxia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MTHFR</italic>, <italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">180</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Negative regulation of synaptic transmission, glutamatergic</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Adenohypophysis development</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of synaptic transmission, GABAergic</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SYN3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Behavioral response to ethanol</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of dopamine secretion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>CHRNA7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dopamine biosynthetic process</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.4</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-18-00527-t005" position="float">
<object-id pub-id-type="pii">ijms-18-00527-t005_Table 5</object-id>
<label>Table 5</label>
<caption>
<p>GeneAnalytics profiling of high match score phenotypes to 23 overlapping genes for autism spectrum disorder, bipolar disorder and schizophrenia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Phenotypes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Genes Matched to Phenotypes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">No. of Genes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Score</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Behavioral despair</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>GSK3B</italic>, <italic>CACNA1C</italic>, <italic>CSMD1</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">28</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24.8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hypoactivity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>FOXP2</italic>, <italic>ANK3</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">314</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal serotonin level</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>FOXP2</italic>, <italic>TPH2</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">32</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal response to novel object</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>FOXP2</italic>, <italic>TPH2</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">44</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">22.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal GABAergic neuron morphology</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>BDNF</italic>, <italic>CHRNA7</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal prepulse inhibition</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>DISC1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal social Investigation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>SYN3</italic>, <italic>CACNA1C</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increase aggression towards males</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>TPH2</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">64</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small cerebellum</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MTHFR</italic>, <italic>FOXP2</italic>, <italic>ANK3</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">67</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19.8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decrease exploration in new environment</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>GSK3B</italic>, <italic>FOXP2</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">79</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18.9</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal CNS synaptic transmission</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">79</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18.9</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Premature death</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MTHFR</italic>, <italic>FOXP2</italic>, <italic>ANK3</italic>, <italic>TPH2</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">830</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decrease startle reflex</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>FOXP2</italic>, <italic>CSMD1</italic>, <italic>DISC1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">84</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decrease anxiety-related response</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>HTR2A</italic>, <italic>CHRNA7</italic>, <italic>DISC1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">89</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increase dopamine level</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic>, <italic>FOXP2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">31</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal vocalization</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>FOXP2</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">37</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperactivity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>NRG1</italic>, <italic>BDNF</italic>, <italic>CSMD1</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">272</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased thigmotaxis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>CACNA1C</italic>, <italic>CSMD1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">45</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal serotonergic neuron morphology</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>TPH2</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal response to novel odor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal latent inhibition of conditioning</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>DISC1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Impaired coordination</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>FOXP2</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">309</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal learning/memory/conditioning</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>GSK3B</italic>, <italic>CACNA1C</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">49</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Limp posture</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased serotonin Level</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>TPH2</italic>, <italic>DISC1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Postnatal growth retardation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MTHFR</italic>, <italic>FOXP2</italic>, <italic>TPH2</italic>, <italic>BDNF</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">581</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal pituitary gland physiology</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal inhibitory postsynaptic currents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>SYN3</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">60</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small nodose ganglion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Complete postnatal lethality</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>FOXP2</italic>, <italic>ANK3</italic>, <italic>TCF4</italic>, <italic>BDNF</italic>, <italic>CACNA1C</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">375</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small petrosal ganglion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>BDNF</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14.0</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased somatotroph cell number</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal grooming behavior</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>SLC6A3</italic>, <italic>MAOA</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abnormal excitatory postsynaptic currents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>NRG1</italic>, <italic>SYN3</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">72</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased left ventricle systolic pressure</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>NRG1</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hunched posture</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>MAOA</italic>, <italic>BDNF</italic>, <italic>DRD2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">78</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13.3</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>